ADC Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $19,248 | $20,033 | $23,058 | $16,427 |
Gross Profit | 16,899 | 16,418 | 21,359 | 15,225 |
EBITDA | -45,952 | -20,394 | 6,314 | -27,452 |
EBIT | -20,619 | 6,201 | -27,574 | |
Net Income | -16,565 | -32,968 | -6,409 | -40,966 |
Net Change In Cash | 19,248 | 20,033 | 23,058 | 16,427 |
Free Cash Flow | -11,807 | -29,742 | -31,134 | -29,630 |
Cash | 219,107 | 231,008 | 261,338 | 234,738 |
Basic Shares | 155,016 | 154,142 | 150,301 | 136,446 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $81,357 | $70,837 | $69,558 | $209,908 |
Gross Profit | 73,683 | 64,888 | 67,029 | 206,607 |
EBITDA | -89,271 | -102,649 | -145,827 | -107,698 |
EBIT | -91,147 | -105,925 | -149,094 | -110,086 |
Net Income | -142,623 | -157,846 | -240,053 | -157,128 |
Net Change In Cash | 81,357 | 70,837 | 69,558 | 209,908 |
Free Cash Flow | -141,438 | -124,702 | -121,902 | -137,371 |
Cash | 261,338 | 250,867 | 278,598 | 326,441 |
Basic Shares | 127,067 | 97,159 | 81,712 | 78,152 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.11 |
2026-03-31 | -$0.21 |
2025-12-31 | -$0.04 |
2025-09-30 | -$0.30 |